The European Medicines Agency has issued a marketing authorisation for Orexo and MundiPharma’s Zubsolv (buprenorphine and naloxone) for opioid dependence.
News
Janssen’s Zytiga approved for earlier use in prostate cancer
European regulators are allowing earlier use of Janssen’s Zytiga in the treatment pathway for metastatic prostate cancer.
EMA move: “London’s loss is Amsterdam’s gain”
Amsterdam has been named as the new home of the European Medicines Agency, triggering the start of an “ambitious” relocation programme that must be completed within 16 months.
Public largely unaware of obesity cancer link, study finds
New research shows that public awareness of the risks of obesity and its links with cancer continues to be low, according to a study published in the Journal of Public Health.
Bayer’s Stivarga wins NICE approval for GIST
Bayer’s Stivarga has been recommended by the National Institute for Health and Care Excellence as a treatment for some patients with gastrointestinal stromal tumours (GIST).
Roche’s Hemlibra reduces bleeds in haemophilia A patients
Roche’s Hemlibra has hit key targets in a Phase III trial assessing its effectiveness in preventing bleeds in adults and adolescents with haemophilia A without inhibitors to factor VIII.
EU nod for first Herceptin biosimilar
European regulators have approved the first biosimilar of Roche’s blockbuster biologic Herceptin, issuing a green light for Samsung Bioepis’ Ontruzant.
COPD survey reveals gaps in care
A survey of 500 people across Britain diagnosed with chronic obstructive pulmonary disease (COPD) has revealed that almost a third (31 percent) feel their treatment is not adequately controlling their condition.
FDA widens scope of Pfizer’s Sutent in kidney cancer
The US Food and Drug Administration has cleared Pfizer’s Sutent for adjuvant treatment of adults at a high risk of their kidney cancer returning after a kidney has been removed.
Roche bags new approvals for Hemlibra, Gazyva
US regulators have issued a green light for Roche’s haemophilia A therapy Hemlibra and also expanded the scope of Gazyva to include untreated advanced follicular lymphoma.
New data show public support for tax rises to fund NHS
Fifty-eight percent of adults talking part in a YouGov poll have backed a one percent rise in National Insurance tax to increase public spend on the NHS.
Fill out the MCQ today
PharmaTimes Clinical Researcher of the Year – The Americas is now open for entry.
International Clinical Researcher of the Year – Register your details to start Stage 1
The PharmaTimes International Clinical Researcher of the year competition is now open for entry
EU advisors back expanding use of Adcetris
Takeda’s Adcetris could soon be on the market in Europe as a second-line treatment for adults with CD30-positive cutaneous T-cell lymphoma (CTCL) after regulatory advisors backed expanding the drug’s scope.
Green light for minimum alcohol pricing in Scotland
Health officials have welcomed a decision by the Supreme Court that allows the introduction of minimum unit pricing in Scotland, which sets a minimum unit price of 50 pence per unit for alcohol.
